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Department of Pharmacology and Toxicology, Radboud university medical center, P.O. Box 9101, 6500 HB Nijmegen, The NetherlandsIn this issue of EBioMedicine, Kishi et al. report on their intriguing
ﬁnding that pre-treatment with meclizine prevents renal ischemia–
reperfusion injury in male mice (Kishi et al. 2015). Furthermore, they
provide a potential mode of action of this reno-protective intervention:
intracellular accumulation of phosphoethanolamine, which in turn
activates glycolysis and attenuates mitochondrial oxidative phosphory-
lation. These metabolic changes are associated with reduced ROS
formation and reperfusion injury with secondary effects on IR-related
inﬂammation and subsequent collateral damage. The authors must be
congratulated for this timely contribution in this ﬁeld, which stands in
a long tradition from this group in their quest for new therapeutic
options to prevent renal injury (Bonventre and Weinberg 1992).
Ischemia–reperfusion injury is an important determinant of the clinical
success of renal transplantation—it is likely involved in the pathogenesis
of contrast nephropathy and plays an important role in renal injury due
to shock as occurs in sepsis, or major (cardiovascular) surgery. There-
fore, prevention of renal ischemia–reperfusion injury with a clinically
safe and effective intervention is expected to have a signiﬁcant impact
on health care and survival (CHERTOW et al., 2005). In that regard,
the translation of the reported therapeutic action of meclizine from
mice to men seems (at least theoretically) rather straightforward
since this drug is available as an over the counter drug both in Europe
and the US as tablets of 12.5 mg to prevent motion sickness. A typical
dose in humans is 25 mg in adults and in children this dose is reduced
(12.5 mg in children N 6 years and 6.25 mg in children 3-6 years).
However, this is not the ﬁrst intervention in animals that claims to
prevent ischemia–reperfusion injury in the kidney or other vital organs
such as brain and heart. Other successful interventions in animalmodels
include ischemic conditioning (protective effect of short bouts of non-
injurious ischemia and reperfusion of target or remote organ (WEVER
et al. 2012a)), diannexin, metformin, dipyridamole, erythropoietin,
adenosine, statins, cyclosporine and many others. This list includes
drugs that are easily available by prescription or are not difﬁcult to
apply (remote ischemic conditioning). Nevertheless, evidence-based
clinical management to prevent renal injury is still limited to optimiza-
tion of organ perfusion and prevention of exposure to drugs that are
toxic to the hypo-perfused kidney (i.e. aminoglycosides, NSAIDs and in-
hibitors of the renin-angiotensin-aldosterone system) because clinicalDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.07.035.
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are not conclusive or negative (Zuk andBonventre 2015, ELMESSAOUDI
et al. 2015b, EL MESSAOUDI et al. 2015a, ROSS et al. 2005). Thus, the
conclusion is justiﬁed that, at least up to now, strategies that prevent is-
chemia–reperfusion injury in pre-clinical models are stuck in transla-
tion to the clinic (RONGEN and WEVER 2015).
What is the reason for these disappointments in the clinical develop-
ment of promising pre-clinical interventions to prevent ischemia–
reperfusion injury? First, as reviewed recently, pre-clinical studies in
the ﬁeld of ischemia–reperfusion often have serious methodological
ﬂaws, resulting in potential serious bias of results (RONGEN and
WEVER 2015). In that regard, we should however compliment Kishi
et al. for their accurate report of their methodology and ﬁndings:
some important basic methodological essentials were addressed such
as drop-outs, randomization and blinding. However, there is still some
doubt: although most essential experimental conditions were well
monitored, blood pressure and/or renal perfusion was not measured
throughout the experiments. Differences in blood pressure (and there-
fore renal perfusion) between meclizine treated and control animals
could theoretically have confounded the results, in particular when
these differences occurred during reperfusion.
Assuming that the claimed effect of meclizine in male mice on renal
ischemia–reperfusion injury is real, there are still a couple of uncer-
tainties that hinder translation to humans. The observation might be
species and/or gender speciﬁc (WEVER et al. 2012b). Replication in
larger mammals including both sexes is therefore warranted before
doing an (expensive) clinical trial. More importantly, Kishi et al. applied
a very high intraperitoneal dose of 100mg/kg. Unfortunately,we are not
informed about the achieved plasma levels of meclizine in these ani-
mals. Although the mice may have tolerated this high dose surprisingly
well, we are not sure whether this exposure to meclizine can be repli-
cated in humans without inducing serious and unacceptable adverse
events such as coma, epileptic insults and hypotension, known adverse
events of meclizine overdose in humans. To overcome this problem, we
may needmore speciﬁc inhibitors of phosphoethanolaminemetabolism
which should be fully evaluated both pre-clinically and in phases 1–3
clinical studies before they can be applied in practice. Another issue is
the age and health status of the animals. The healthy and relatively
young animals as used by Kishi et al. differ from the aged population
of patients with co-morbidity and co-medication who are at particular
risk for renal ischemia–reperfusion injury. Replication of ﬁndings in
more representative animal models are essential for appropriateC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1013G.A. Rongen / EBioMedicine 2 (2015) 1012–1013translation to the clinic. Finally, meclizine was tested in an optimized
and highly standardized experimental design with respect to timing of
the intervention and duration of ischemia and reperfusion. This differs
from the clinical reality inwhich patients experience a variable duration
and severity of renal hypoperfusion and often present after the ischemic
event has already taken place.
In conclusion, Kishi et al. report an intriguing ﬁnding that accumula-
tion of phosphoethanolamine prevents renal ischemia–reperfusion
injury. Furthermore, they show that this form ofmetabolic renal protec-
tion may be involved in the renal beneﬁts of a high dose of meclizine
given prior to a standardized period of renal ischemia and reperfusion
in healthy male mice. Although meclizine is an over the counter drug
that should be easily available for trials in humans, many questions
and uncertainties need to be solved to allow appropriate translation to
humans.
The author does not report competing interests.
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